What the price includes at each tier

Three price points cover the full range of treatment volumes at London Cartilage Clinic, and every one of them is bundled to include the same set of components — so the figure quoted at the outset is the figure patients pay.

• £3,000 — one box (2.3 mL): the starting tier, appropriate for most patients with a single focal area to treat.
• £5,500 — two boxes: indicated where a larger surface area or more than one compartment within the same joint requires additional scaffold volume.
• £8,000 — three boxes: reserved for the most extensive presentations, typically involving multiple joint compartments or a particularly large defect area.

In each case, the fee covers the initial consultation, all ultrasound imaging used to guide the injection on the day, the ChondroFiller collagen scaffold product itself, the ultrasound-guided outpatient injection, intravenous antibiotic cover administered at the time of treatment, and a six-week follow-up appointment. There are no separate charges for the imaging session, the antibiotic cover, or the post-treatment review.

The same pricing structure applies regardless of which joint is being treated — knee, hip, ankle, shoulder, and other suitable joints are billed at identical rates. Patients attending a consultation can therefore budget from a published schedule without needing to allow for joint-specific surcharges or itemised add-ons.

Why the number of boxes drives the fee

The fee structure follows a simple logic: the product drives the price. ChondroFiller is a CE-marked Class III collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany and supplied as a prescription medical device — not a generic injectable. Importing and dispensing it under prescription carries significant product cost, and that cost is the largest single component within each tier.

How many boxes a patient requires is a clinical determination, not a patient choice. Defect size, joint volume, and whether coverage is needed across more than one site within the same joint all inform the dosage decision. A clinician will assess pre-treatment imaging and carry out a physical review before confirming which volume applies; patients cannot select a tier in advance of that assessment.

A useful structural reference point: Arthrosamid, a non-regenerative polyacrylamide hydrogel used at the same clinic for a different indication, carries an identical three-tier pricing schedule. The parallel is not a clinical comparison — the two products work through entirely different mechanisms and address different aspects of joint disease — but it does confirm that the volume of prescription product dispensed, rather than the complexity of the outpatient procedure itself, is what sets the fee at each level.

CCSD codes and why this pathway is self-pay

Two CCSD codes — W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy) — exist within UK billing for ChondroFiller-based treatment, but they belong to the Liquid Cartilage surgical procedure: a theatre-based, arthroscopic pathway that is distinct from the outpatient injection route described in this article. Neither code applies to the ultrasound-guided injection appointment.

Because no equivalent CCSD code has been established for the ChondroFiller injection pathway, the treatment sits outside both NHS provision and standard private medical insurance (PMI) reimbursement. Patients should plan the full quoted fee as an out-of-pocket cost; sending an insurance pre-authorisation request for the injection route is unlikely to be productive under current insurer recognition.

This distinction matters in both directions. Patients who hold PMI and are considering cartilage treatment should raise the surgical Liquid Cartilage route with their clinician — Bupa, Aviva, and WPA have the strongest reported track record of granting pre-authorisation against W3111 and W8500, though approval is never guaranteed and written pre-authorisation must always be confirmed before any treatment proceeds (position correct as of late 2025; subject to change). Suitability for the surgical route involves separate clinical criteria and is not assumed simply because the injection pathway has been assessed.

For those pursuing the injection route, the all-inclusive pricing covered in the preceding sections represents the complete out-of-pocket cost — there are no additional claims processes or reimbursement steps involved.

Combination therapy and advanced-tier costs

For patients with Kellgren–Lawrence Grade III or IV osteoarthritis, a single-product injection may not address the full picture of joint disease. At that severity, two anatomically distinct targets may be identified — the load-bearing cartilage surface and the synovial lining — and a combined protocol can be delivered in a single clinic appointment.

Dual injection: ChondroFiller + Arthrosamid — £6,000

The combination pairs ChondroFiller with Arthrosamid, a polyacrylamide hydrogel. The two products are not variations of the same treatment: ChondroFiller provides the regenerative scaffold at the cartilage defect (the mechanism is covered in the preceding section), while Arthrosamid acts on the synovial membrane through a different process entirely. Treating them as interchangeable would misrepresent what each contributes. A combined appointment for this dual-injection protocol costs £6,000.

Tri-Active Therapy — £11,000

Adding autologous mesenchymal stem cell (MSC) therapy escalates the combination to the Tri-Active Therapy tier. The MSC component carries a £5,000 premium over the £6,000 dual-injection base, bringing the total to £11,000. This tier is indicated where the assessing clinician considers a broader regenerative stimulus appropriate for particularly advanced or end-stage presentations.

Lifetime Programme

A longitudinal maintenance programme is also available, comprising annual peptide protocols, yearly MRI review, and bi-annual ChondroFiller top-up injections. Fees are not published at a fixed tariff — the programme is structured around each patient's individual maintenance schedule, and the cost is bespoke to the frequency and scope of top-up treatment agreed at consultation. Patients who want a working budget figure should raise this during their initial assessment, at which point a realistic figure can be mapped to their clinical trajectory.

How the injection cost compares to the surgical alternative

The Liquid Cartilage surgical procedure — a day-case operation using the same ChondroFiller collagen scaffold — is priced at a flat £9,800. Against the injection fee schedule of £3,000 to £8,000, that is a meaningful differential, but the gap only makes sense when read in clinical context.

The two pathways are not interchangeable options between which a patient chooses on cost grounds alone. Clinical factors — defect characteristics, the joint involved, overall health, and candidacy for a general anaesthetic — determine which route a clinician recommends. The injection route carries no upper age limit and no defect-size ceiling, a relevant consideration for patients who may not be suitable surgical candidates. The surgical alternative involves theatre admission, general anaesthesia, and a recovery period that differs substantially from the same-day discharge that follows an outpatient injection appointment.

For patients weighing both routes, the practical differences — recovery demands, return to normal activity, and the logistics of a hospital day-case versus a Harley Street outpatient appointment — form part of the cost picture as much as the headline figures do. A single-box injection at £3,000 and the surgical pathway at £9,800 are not two price points for the same clinical outcome. The factors that tip the decision toward one or the other — defect size, joint loading pattern, surgical fitness — are best established through specialist assessment of the individual joint and clinical history.

Building your budget before a consultation

Three practical steps are worth completing before an appointment.

Check imaging requirements. The bundled fee covers the ultrasound imaging used on the day of treatment, but pre-consultation MRI or X-ray — if not already available — may carry an additional cost. Confirm this at the time of booking.

Clarify PMI status carefully. Patients with private medical insurance should contact their insurer before attending and be specific: they are enquiring about an outpatient injection pathway, not the arthroscopic surgical route covered under CCSD codes W3111 or W8500. That distinction matters; a misaligned pre-authorisation enquiry is straightforward to avoid with precise wording.

Let the consultation set the tier. The appropriate box volume — and therefore which price point applies — is established through imaging review and clinical examination at the first appointment. Budgeting for the single-box figure with headroom to the next tier is a reasonable starting position before that assessment takes place.

For patients outside London, the wider MSK Doctors group has sites in Lincolnshire and Grantham where delivery may be more practical. London appointments are bookable via londoncartilage.com — the consultation itself is where the clinical picture and the final cost figure converge.